

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
				Application Number	10/560,653
				Filing Date	November 20, 2006
				First Named Inventor	David B. Weiner
				Art Unit	1648
				Examiner Name	Bao Q. Li
Sheet	1	of	4	Attorney Docket Number	130694.02201

<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
AA	US-4,722,848		02-02-1988	Paoletti, et al.	
AB	US-4,945,050		07-31-1990	Sanford, et al.	
AC	US-5,017,487		05-21-1991	Stunnenberg, et al.	
AD	US-5,036,006		07-30-1991	John C. Sanford, et al.	
AE	US-5,077,044		12-31-1991	Bruce Arnold D. Stocker	
AF	US-5,110,587		05-05-1992	Enzo Paoletti	
AG	US-5,112,749		05-12-1992	Robert N. Brey	
AH	US-5,174,993		12-29-1992	Enzo Paoletti	
AI	US-5,223,424		06-29-1993	Mark D. Cochran	
AJ	US-5,225,335		07-06-1993	Enzo Paoletti	
AK	US-5,240,703		08-31-1993	Mark D. Cochran	
AL	US-5,242,829		09-07-1993	Dennis L. Panicali	
AM	US-5,294,441		03-15-1994	Roy Curtiss	
AN	US-5,294,548		03-15-1994	James H. McLinden	
AO	US-5,310,668		05-10-1994	Ronald W. Ellis	
AP	US-5,387,744		02-07-1995	Roy Curtiss	
AQ	US-5,389,368		02-14-1995	Roy Curtiss	
AR	US-5,424,065		06-13-1995	Roy Curtiss	
AS	US-5,451,499		09-19-1995	Mark D. Cochran	
AT	US-5,453,364		09-26-1995	Enzo Paoletti	
AU	US-5,462,734		10-31-1995	Geoffrey J. Letchworth	
AV	US-5,470,734		11-28-1995	Paulus J. A. Sondermeijer	
AW	US-5,482,713		01-09-1996	Enzo Paoletti	
AX	US-5,580,859		12-03-1996	Philip L. Felgner	
AY	US-5,593,972		01-14-1997	David B. Weiner	
AZ	US-5,593,972		01-14-1997	David B. Weiner	
BA	US-5,676,594		10-14-1997	Egbertus M. Joosten	
BB	US-5,703,055		12-30-1997	Philip L. Felgner	
BC	US-5,739,118		04-14-1998	Richard A. Carrano	
BD	US-5,817,634		10-06-1998	Elias Meezan	
BE	US-5,830,876		11-03-1998	David B. Weiner	
BF	US-5,962,425		10-05-1999	Joseph A. Walder	
BG	US-5,981,505		11-09-1999	David B. Weiner	

Examiner Signature	/Bao Li/	Date Considered	10/08/2008
--------------------	----------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Applicant's unique citation designation number (optional).<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.<sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BL/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<i>Application Number</i>	10/560,653
				<i>Filing Date</i>	November 20, 2006
				<i>First Named Inventor</i>	David B. Weiner
				<i>Art Unit</i>	1648
				<i>Examiner Name</i>	Bao Q. Li
(Use as many sheets as necessary)					
Sheet	2	of	4	<i>Attorney Docket Number</i>	130694.02201

Examiner Signature	/Bao Li/	Date Considered	10/08/2008
--------------------	----------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Applicant's unique citation designation number (optional).<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.<sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BL/

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<i>Application Number</i>	10/560,653
<i>(Use as many sheets as necessary)</i>				<i>Filing Date</i>	November 20, 2006
				<i>First Named Inventor</i>	David B. Weiner
				<i>Art Unit</i>	1648
				<i>Examiner Name</i>	Bao Q. Li
Sheet	3	of	4	<i>Attorney Docket Number</i>	
130694.02201					

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	BJ	Chaudhary, V.K., et al., "A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins," <i>Proc. Natl. Acad Sci. USA</i> (1990) 87(3):1066-70.		
	BK	Chiu et al., "The c-Fos protein interacts with c-Jun/AP-1 to stimulate transcription of AP-1 responsive genes," <i>Cell</i> (1988) 54(2):541-552.		
	BL	Durkop, H et al., "Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease," <i>Cell</i> (1992) 68(3):421-427.		
	BM	Franklin et al., "Constitutively active MAP kinase kinase (MEK1) stimulates SAP kinase and c-Jun transcriptional activity in U937 human leukemic cells," <i>Oncogene</i> (1995) 11(11):2365-74.		
	BN	Gilmore et al., "The I kappa B proteins: members of a multifunctional family," <i>Trans Genet</i> (1993) 9(12):427-33.		
	BO	Howell, M.D., et al., "Limited T-cell receptor beta-chain heterogeneity among interleukin 2 receptor-positive synovial T cells suggests a role for superantigen in rheumatoid arthritis.," <i>Proc. Nat. Acad. Sci USA</i> (1991) 88:10921-10925.		
	BP	Lee et al., "Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements," <i>Cell</i> (1987) 49(6):741-752.		
	BQ	Meyer R., et al., "Cloning of the DNA-binding subunit of human nuclear factor kappa B: the level of its mRNA is strongly regulated by phorbol ester or tumor necrosis factor alpha.," <i>Proc. Natl. Acad. Sci USA</i> (1991) 88(3):966-970.		
	BR	Oksenberg, J.R., et al., "Limited heterogeneity of rearranged T-cell receptor V $\alpha$ transcripts in brains of multiple sclerosis patients," <i>Nature</i> (1990) 345(6264):344-346.		
	BS	Paliard, X., et al., "Evidence for the effects of a superantigen in rheumatoid arthritis.," <i>Science</i> (1991) 253(5017):325-329.		

Examiner Signature	/Bao Li/	Date Considered	10/08/2008
--------------------	----------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BL/

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
				<i>Application Number</i>	10/560,653
				<i>Filing Date</i>	November 20, 2006
				<i>First Named Inventor</i>	David B. Weiner
				<i>Art Unit</i>	1648
				<i>Examiner Name</i>	Bao Q. Li
Sheet	4	of	4	<i>Attorney Docket Number</i>	130694.02201

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	BT	Rauscher et al., "Fos-associated protein p39 is the product of the jun proto-oncogene," <i>Science</i> (1988) 240(4855):1010-1016.		T <sup>2</sup>
	BU	Smith, C.A., et al., "CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF," <i>Cell</i> (1993) 73(7):1349-1360.		
	BV	Williams, W.V., et al., "Restricted heterogeneity of T cell receptor transcripts in rheumatoid synovium," <i>J Clin. Invest.</i> (1992) 90(2):326-333.		
	BW	Wucherpfennig, K.W., et al., "Shared human T cell receptor V beta usage to immunodominant regions of myelin basic protein," <i>Science</i> (1990) 248(4958):1016-1019.		
	BY	Murakami, M. "High-level expression of exogenous genes by replication-competent retrovirus vectors with an internal ribosomal entry site." <i>Gene</i> (1997) 202:23-29.		
	BZ	Clement, A. et al., "Prime-boost immunization with DNA and modified vaccine virus Ankara vector expressing herpes simplex virus-2 glycoprotein d elicits greater specific antibody and cytokine responses than DNA vaccine alone, 1066-1072.		
	CA	Luo, Y. et al., "Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine." <i>PNAS</i> (2003) 100: 8850-8855.		

Examiner Signature	/Bao Li/	Date Considered	10/08/2008
--------------------	----------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BL/